Published in J Gene Med on November 01, 2009
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther (2011) 1.42
Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses (2010) 1.17
Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol Cancer Ther (2010) 1.02
SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors. Mol Ther (2013) 0.86
Retargeting of gene expression using endothelium specific hexon modified adenoviral vector. Virology (2013) 0.85
Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. Cancer Gene Ther (2011) 0.82
Adrenal gland infection by serotype 5 adenovirus requires coagulation factors. PLoS One (2013) 0.76
Promising oncolytic agents for metastatic breast cancer treatment. Oncolytic Virother (2015) 0.76
Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy. Mol Ther Oncolytics (2015) 0.76
Adenoviruses with an αvβ integrin targeting moiety in the fiber shaft or the HI-loop increase tumor specificity without compromising antitumor efficacy in magnetic resonance imaging of colorectal cancer metastases. J Transl Med (2010) 0.75
Mutation of the fiber shaft heparan sulphate binding site of a 5/3 chimeric adenovirus reduces liver tropism. PLoS One (2013) 0.75
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment. PLoS One (2017) 0.75
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65
Harmful impact of EU clinical trials directive. BMJ (2006) 4.85
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res (2013) 3.22
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol (2013) 2.70
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med (2010) 2.58
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol (2007) 2.42
Site-specific survival rates for cancer of unknown primary according to location of metastases. Int J Cancer (2013) 2.24
Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology (2002) 2.19
SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res (2005) 2.05
Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res (2005) 1.94
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther (2010) 1.91
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther (2003) 1.86
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst (2009) 1.80
High frequency of BRAF V600E mutations in ameloblastoma. J Pathol (2014) 1.79
Mitochondrial myopathy induces a starvation-like response. Hum Mol Genet (2010) 1.78
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res (2002) 1.74
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol (2009) 1.70
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 1.69
Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. Mol Ther (2007) 1.68
Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther (2003) 1.66
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther (2011) 1.60
Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol (2008) 1.58
Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther (2012) 1.57
Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology (2005) 1.56
Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. Cancer (2006) 1.53
Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One (2011) 1.50
Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res (2003) 1.50
LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat Genet (2008) 1.46
Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res (2005) 1.46
Cytokine-conditioned dendritic cells induce humoral tolerance to protein therapy in mice. Hum Gene Ther (2012) 1.44
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res (2011) 1.42
Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res (2007) 1.41
CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res (2010) 1.39
Intussusception and spontaneous amputation of the esophagus. J Thorac Cardiovasc Surg (2002) 1.38
Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm (2010) 1.36
Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol (2002) 1.35
Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res (2005) 1.34
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res (2010) 1.33
Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res (2012) 1.29
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res (2012) 1.28
Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol (2006) 1.27
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer (2011) 1.26
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res (2009) 1.24
15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res (2009) 1.23
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst (2008) 1.22
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther (2013) 1.22
Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A (2008) 1.20
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther (2007) 1.19
An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther (2012) 1.18
Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol (2012) 1.18
Modified adenoviruses for cancer gene therapy. Int J Cancer (2004) 1.18
Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. J Virol (2011) 1.17